The Patent Finder
JP

Janssen Pharmaceutica N.V.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Janssen-Cilag S.A. (to 2010)

458 patents currently held

168 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.

The next US patent term in the Janssen Pharmaceutica N.V. portfolio ends in Mar 2027, and more of its terms end in 2037 (65) than in any other year. from the record

Of the 168 now held by other companies, 24 were conveyed to Astex Therapeutics Ltd. in the filing they arrived in, and 144 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
79
Ending by 2030
Mar 2027
Next term end
321
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Treatment of Sleep-Wake Disorders US 8,440,715
The most cited patent in this portfolio, cited by 82 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2031.
Ends Jun 2031 · High confidence
Also notable
Anti-Vista Antibodies and Fragments US 11,242,392
Cited by 15 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2035.
Ends Jul 2035 · Medium confidence
Also notable
Novel Compounds as Opioid Receptor Modulators US 7,741,356
Cited by 66 later US patents, top 25% of utility patents granted in 2010 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Ends Feb 2031 · Medium confidence

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 111 later US patents, top 5% of utility patents granted in 2016 in our data. Protection runs to 2033.
Ends Dec 2033 · High confidence
Also notable
Cited by 42 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Ends Nov 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 4 fees due Nov 23 to 26, 2026 · next Nov 23
  • 9 fees due Dec 11 to 30, 2026 · next Dec 11
  • 13 fees due Jan 4 to 30, 2027 · next Jan 4
  • 8 fees due Feb 6 to 25, 2027 · next Feb 6
  • 4 fees due Mar 1 to 26, 2027 · next Mar 1
  • 6 fees due Apr 1 to 30, 2027 · next Apr 1
  • 13 fees due May 3 to 28, 2027 · next May 3
  • 8 fees due Jun 12 to 30, 2027 · next Jun 12
  • 7 fees due Jul 7 to 30, 2027 · next Jul 7
  • 6 fees due Aug 6 to 18, 2027 · next Aug 6
  • 6 fees due Sep 1 to 17, 2027 · next Sep 1
  • 9 fees due Oct 2 to 30, 2027 · next Oct 2
  • 9 fees due Nov 5 to 21, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • Oct 26Assignment recorded on 1 record: Johnson & Johnson and 2 others to Janssen Pharmaceutica N.V. Recorded Oct 26, 2026, executed Apr 14, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76504, frame 646.
  • Oct 21Assignment recorded on 1 record: Janssen Research & Development, LLC to Janssen Pharmaceutica N.V. Recorded Oct 21, 2026, executed Oct 15, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76450, frame 293.
  • 12 of the patents on this record were granted since Aug 24, 2026
  • 32 terms have ended since Aug 24, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,738,649Tetrahydro-Pyrimidoazepines as Modulators of TRPV1
In force
 · Medium confidence
In forceMedium confidence
US 8,895,584Inhibitors of C-Fms Kinase
In force
 · Medium confidence
In forceMedium confidence
US 8,933,091Method of Inhibiting C-Kit Kinase
In force
 · Medium confidence
In forceMedium confidence
US 7,776,8822-Amino-3,4-Dihydro-QUINOLINE Derivatives Useful as Inhibitors of Beta-Secretase (BACE)
In force
 · High confidence
In forceHigh confidence
US 9,422,293Tetrahydro-Pyrimidoazepines as Modulators of TRPV1
In force
 · Low confidence
In forceLow confidence
US 7,678,786Benzoazepin-Oxy-Acetic Acid Derivatives as Ppar-Delta Agonists Used for the Increase of Hdl-C, Lower Ldl-C and Lower Cholesterol
In force
 · High confidence
In forceHigh confidence
US 7,893,058Imidazolopyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases
In force
 · High confidence
In forceHigh confidence
US 7,767,679Sulfonylamino-Derivatives as Novel Inhibitors of Histone Deacetylase
In force
 · High confidence
In forceHigh confidence
US 7,786,158Novel Compounds as Opioid Receptor Modulators
In force
 · Medium confidence
In forceMedium confidence
US 8,940,743PIPERIDIN-4-YL-PYRIDAZIN-3-Ylamine Derivatives as Fast Dissociating Dopamine 2 Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
10 of 458 patents shown.
Pro members see all 458.
Pro members: see all 458 patents
Also on record, not counted in the 458: 168 patents in force now held by others · 505 patents ended · 235 applications pending · 456 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited